The evolving definition of carcinogenic human papillomavirus

Infectious Agents and Cancer

Volumn 4, Issue 1, 2009, Pages

  Castle, Philip E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PREVENTION; CANCER SCREENING; GENOTYPE; HEALTH PROGRAM; HUMAN; PREVALENCE; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS;

EID: 66649093505     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-4-7     Document Type: Article

References (28)

1. Human Papillomaviruses. [90]. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Lyon, France, IARC 2007 Ref Type: Serial (Book, Monograph)
2. Carcinogenicity of human papillomaviruses. V Cogliano R Baan K Straif Y Grosse B Secretan F El Ghissassi, Lancet Oncol 2005 6 204 10.1016/S1470-2045(05) 70086-3 15830458
3. A review of human carcinogens Part B: biological agents. V Bouvard R Baan K Straif Y Grosse B Secretan GF El, Lancet Oncol 2009 10 321 322 10.1016/S1470-2045(09)70096-8 19350698
4. The carcinogenicity of human papillomavirus types reflects viral evolution. M Schiffman R Herrero R Desalle A Hildesheim S Wacholder RA Cecilia, Virology 2005 20 337 76 84 10.1016/j.virol.2005.04.002
5. A study of the impact of adding HPV types to cervical cancer screening and triage tests. M Schiffman MJ Khan D Solomon R Herrero S Wacholder A Hildesheim, J Natl Cancer Inst 2005 97 147 150 15657345
6. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. T Hiller S Poppelreuther F Stubenrauch T Iftner, Cancer Epidemiol Biomarkers Prev 2006 15 1262 1267 10.1158/1055-9965.EPI-05-0778 16835321
7. Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. P Muench T Hiller S Probst AM Florea F Stubenrauch T Iftner, Virology 2009 19285702
8. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. S de Sanjose M Diaz X Castellsague G Clifford L Bruni N Munoz, Lancet Infect Dis 2007 7 453 459 10.1016/S1473-3099(07)70158-5 17597569
9. The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses:An ALTS Report. PE Castle MH Stoler D Solomon M Schiffman, Am J Clin Pathol 2007 127 805 815 10.1309/PT3PNC1QL2F4D2VL 17439841
10. Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia-Grade 2. PE Castle M Schiffman CM Wheeler D Solomon, Obstet Gynecol 2009 113 18 25 19104355
11. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. N Spardy A Duensing D Charles N Haines T Nakahara PF Lambert, J Virol 2007 81 13265 13270 10.1128/JVI.01121-07 17898070
12. Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. HK Wang AA Duffy TR Broker LT Chow, Genes Dev 2009 23 181 194 10.1101/gad.1735109 19131434
13. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. MH Stoler M Schiffman, JAMA 2001 285 1500 1505 10.1001/jama.285.11.1500 11255427
14. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). PE Castle JT Cox J Jeronimo D Solomon CM Wheeler PE Gravitt, Obstet Gynecol 2008 111 847 856 18378743
15. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. M Arbyn M Kyrgiou C Simoens AO Raifu G Koliopoulos P Martin-Hirsch, BMJ 2008 337 a1284 10.1136/bmj.a1284 18801868
16. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. M Kyrgiou G Koliopoulos P Martin-Hirsch M Arbyn W Prendiville E Paraskevaidis, Lancet 2006 367 489 498 10.1016/S0140-6736(06)68181-6 16473126
17. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. JS Smith L Lindsay B Hoots J Keys S Franceschi R Winer, Int J Cancer 2007 121 621 632 10.1002/ijc.22527 17405118
18. Human papillomavirus genotype specificity of hybrid capture 2. PE Castle D Solomon CM Wheeler PE Gravitt S Wacholder M Schiffman, J Clin Microbiol 2008 46 2595 2604 10.1128/JCM.00824-08 18579716
19. The Expanded Use of HPV Testing in Gynecologic Practice per ASCCP-Guided Management Requires the Use of Well-Validated Assays. MH Stoler PE Castle D Solomon M Schiffman, Am J Clin Pathol 2007 127 1 3 10.1309/RNF3C01JKADQCLKP
20. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. CJ Meijer J Berkhof PE Castle AT Hesselink EL Franco G Ronco, Int J Cancer 2009 124 516 520 10.1002/ijc.24010 18973271
21. Risk assessment to guide the prevention of cervical cancer. PE Castle M Sideri J Jeronimo D Solomon M Schiffman, J Low Genit Tract Dis 2008 12 1 7 10.1097/lgt.0b013e31815ea58b 18162804
22. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. P Naucler W Ryd S Tornberg A Strand G Wadell K Elfgren, J Natl Cancer Inst 2009 101 88 99 10.1093/jnci/djn444 19141778
23. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. MJ Khan PE Castle AT Lorincz S Wacholder M Sherman DR Scott, J Natl Cancer Inst. 2005 97 14 1072 1079 16030305
24. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. F Carozzi M Confortini PD Palma MA Del A Gillio-Tos ML De, Lancet Oncol 2008 18783988
25. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. YL Qiao JW Sellors PS Eder YP Bao JM Lim FH Zhao, Lancet Oncol 2008 9 929 936 10.1016/S1470- 2045(08)70210-9 18805733
26. From India to the world a better way to prevent cervical cancer. M Schiffman S Wacholder, N Engl J Med 2009 360 1453 1455 10.1056/NEJMe0901167 19339726
27. HPV screening for cervical cancer in rural India. R Sankaranarayanan BM Nene SS Shastri K Jayant R Muwonge AM Budukh, N Engl J Med 2009 360 1385 1394 10.1056/NEJMoa0808516 19339719
28. Durable benefits of HPV-based screen-and-treat to 36 months. T Wright L Denny M DeSousa L Kuhn, 25th International Papillomavirus Conference 2009